Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd (SENORES) last reported results for the quarter ended Jun 2026, with sales of ₹180 crore and net profit of ₹30 crore. The stock last traded at ₹1,357, a market capitalisation of ₹6,248 crore, on a P/E of 49.4. Over the past 52 weeks the stock has ranged between ₹700 and ₹1,600. Figures are as of 6 Oct 2026 and are not real time.
Senores Pharmaceuticals Ltd share price and key metrics
- Current price
- ₹1,357
- Market cap
- ₹6,248 cr
- Stock P/E
- 49.4
- Book value
- ₹203
- ROE
- 13.4%
- ROCE
- 15.1%
- Dividend yield
- 0.00%
- 52w high / low
- 1600/700
Metrics as of 6 Oct 2026. Not real time.
Track Senores Pharmaceuticals Ltd
Cruxal reads every Senores Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Senores Pharmaceuticals Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 162%
- TTM
- 51%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 139%
- TTM
- 87%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- 84%
- 10 Years
- %
- 5 Years
- 14%
- 3 Years
- 14%
- Last Year
- 13%
Senores Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹180 cr, up 30.4% from ₹138 cr a year earlier. Net profit was ₹30 cr, up 42.9% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 101 | 103 | 114 | 138 | 162 | 171 | 175 | 180 |
| Expenses | 77 | 77 | 95 | 104 | 112 | 121 | 128 | 126 |
| Operating profit | 23 | 26 | 19 | 34 | 50 | 50 | 47 | 54 |
| OPM % | 23% | 25% | 17% | 25% | 31% | 29% | 27% | 30% |
| Other income | 2 | 5 | 12 | 3 | 5 | 7 | 18 | 3 |
| Interest | 5 | 6 | 5 | 5 | 6 | 5 | 8 | 7 |
| Depreciation | 4 | 4 | 5 | 6 | 8 | 8 | 9 | 10 |
| Profit before tax | 16 | 20 | 21 | 26 | 41 | 45 | 47 | 39 |
| Tax % | 18% | 20% | 13% | 20% | 26% | 25% | 23% | 23% |
| Net profit | 13 | 16 | 18 | 21 | 30 | 34 | 37 | 30 |
| EPS (₹) | 3.86 | 3.73 | 3.87 | 4.28 | 7.03 | 6.87 | 6.86 | 6.67 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Senores Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 14 | 35 | 215 | 398 | 633 | 688 |
| Operating profit | 2 | 13 | 42 | 90 | 168 | 201 |
| OPM % | 14% | 36% | 19% | 23% | 27% | 29% |
| Net profit | 1 | 8 | 33 | 58 | 122 | 131 |
| EPS (₹) | 1.01 | 8.59 | 10.31 | 12.72 | 25.05 | 27.43 |
TTM is the trailing twelve months to the most recent quarter.
Senores Pharmaceuticals Ltd balance sheet
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 9 | 10 | 31 | 46 | 46 |
| Reserves | 28 | 36 | 174 | 740 | 888 |
| Borrowings | 15 | 63 | 258 | 315 | 342 |
| Other liabilities | 8 | 23 | 160 | 126 | 328 |
| Total liabilities | 59 | 131 | 622 | 1,227 | 1,604 |
| Fixed assets | 7 | 27 | 235 | 301 | 755 |
| CWIP | 8 | 34 | 97 | 172 | 17 |
| Investments | 15 | 16 | 0 | 0 | 4 |
| Other assets | 29 | 53 | 289 | 754 | 827 |
| Total assets | 59 | 131 | 622 | 1,227 | 1,604 |
As reported by the company. Total assets equal total liabilities by construction.
Senores Pharmaceuticals Ltd cash flow
| ₹ crore | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | -10 | -1 | -26 | -46 | 62 |
| Cash from investing | -24 | -48 | -54 | -429 | -121 |
| Cash from financing | 36 | 46 | 87 | 573 | -1 |
| Net cash flow | 2 | -3 | 8 | 98 | -60 |
| Free cash flow | -21 | -48 | -78 | -203 | -203 |
| CFO / operating profit | -526% | 3% | -56% | -41% | 45% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Senores Pharmaceuticals Ltd operating ratios
| Per year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | — | 18% | 12% | 11% | 15% |
| Debtor days | 506 | 228 | 191 | 114 | 187 |
| Inventory days | 135 | 89 | 184 | 232 | 130 |
| Days payable | 324 | 388 | 556 | 275 | 340 |
| Cash conversion cycle | 317 | -71 | -182 | 70 | -24 |
| Working capital days | 359 | -7 | -16 | 88 | 132 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Senores Pharmaceuticals Ltd shareholding pattern
Promoters held 45.82% at Jun 2026, broadly unchanged since Jun 2025. FIIs 6.62% and DIIs 9.77%.
| % held | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Promoters | 45.77% | 45.78% | 45.78% | 45.80% | 45.81% | 45.82% | 45.82% |
| FIIs | 4.25% | 4.17% | 3.66% | 4.28% | 3.35% | 3.64% | 6.62% |
| DIIs | 11.77% | 9.66% | 9.51% | 8.62% | 9.32% | 9.62% | 9.77% |
| Public | 38.20% | 40.39% | 41.03% | 41.30% | 41.54% | 40.92% | 37.78% |
| No. of shareholders | 49,518 | 37,653 | 36,389 | 34,917 | 34,401 | 34,126 | 36,498 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Senores Pharmaceuticals Ltd corporate filings
- Senores Pharmaceuticals Limited has informed the Exchange about the certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018 for the quarter ended September 30, 2026Company Updatelow impact
- Senores Pharmaceuticals Limited Announces Successful Conclusion of 9th AGM and Approval of Employee Stock Option Scheme 2026AGM/EGMmedium impact
Cruxal's analysis: Senores Pharmaceuticals Limited has successfully concluded its 9th Annual General Meeting…
Read the full analysis - Senores Pharmaceuticals Concludes 9th AGM; Approves ESOP Scheme 2026AGM/EGMmedium impact
Cruxal's analysis: Senores Pharmaceuticals Limited has successfully concluded its 9th Annual General…
Read the full analysis - Intimation pertaining to closure of trading windowInsider Trading / SASTlow impact
- Senores Pharmaceuticals clarifies recent stock volume movementCompany Updatelow impact
Cruxal's analysis: Senores Pharmaceuticals has issued a clarification regarding the recent movement in the…
Read the full analysis - Senores Pharmaceuticals reports successful USFDA inspection of Apnar Pharma facilityCompany Updatemedium impact
Cruxal's analysis: Senores Pharmaceuticals announced the successful completion of a USFDA inspection at the…
Read the full analysis - Senores Pharmaceuticals Ltd files corrigendum to FY 2025-26 Annual ReportOtherslow impact
Cruxal's analysis: Senores Pharmaceuticals Ltd has submitted a corrigendum to its Annual Report for the…
Read the full analysis - Senores Pharmaceuticals Ltd announces newspaper publication for 9th Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Senores Pharmaceuticals Ltd has fulfilled regulatory requirements under Regulation 30 of…
Read the full analysis - Senores Pharmaceuticals Ltd submits Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Senores Pharmaceuticals has filed its Business Responsibility and Sustainability Report…
Read the full analysis - Senores Pharmaceuticals Ltd submits Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Senores Pharmaceuticals Ltd has filed its Annual Report for the financial year 2025-26 as…
Read the full analysis - Senores Pharmaceuticals Reports Strong FY 2025-26 Performance with 62% Revenue Growth and 108% PAT IncreaseAGM/EGMhigh impact
Cruxal's analysis: Senores Pharmaceuticals Limited delivered robust financial results for FY 2025-26, with…
Read the full analysis - Senores Pharmaceuticals schedules analyst and institutional investor meeting for September 02, 2026Company Updatelow impact
Cruxal's analysis: Senores Pharmaceuticals Limited has announced an upcoming meeting with analysts and…
Read the full analysis - Senores Pharmaceuticals Ltd publishes newspaper notice for upcoming Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Senores Pharmaceuticals Limited has released the mandatory newspaper publication…
Read the full analysis - Senores Pharmaceuticals Announces International Expansion into Mexico and Canada, Board Appointments, and ESOS 2026Othershigh impact
Cruxal's analysis: Senores Pharmaceuticals Limited has announced a strategic international expansion with…
Read the full analysis - Senores Pharmaceuticals provides corporate guarantee for subsidiary Apnar Pharma's credit facilities with ICICI BankCompany Updatelow impact
Cruxal's analysis: Senores Pharmaceuticals Limited has formally notified the exchange regarding the…
Read the full analysis - Senores Pharmaceuticals schedules analyst and institutional investor meet for August 25, 2026Company Updatelow impact
Cruxal's analysis: Senores Pharmaceuticals Limited has announced an analyst and institutional investor…
Read the full analysis - Senores Pharmaceuticals Limited: Promoter Group Executes Inter-se Transfer of 30,000 Shares via GiftInsider Trading / SASTlow impact
Cruxal's analysis: Senores Pharmaceuticals Limited has disclosed an inter-se transfer of 30,000 equity…
Read the full analysis - Senores Pharmaceuticals Limited: Promoter Group Executes Inter-se Off-Market Transfer of 30,000 Equity SharesInsider Trading / SASTlow impact
Cruxal's analysis: Senores Pharmaceuticals Limited has disclosed an inter-se transfer of 30,000 equity…
Read the full analysis - Senores Pharmaceuticals Shareholders Approve Key Related Party Transactions, Enhanced Loan/Guarantee Limits, and IPO Proceeds Utilization ChangesAGM/EGMmedium impact
Cruxal's analysis: Senores Pharmaceuticals Limited announced that its shareholders have approved all eight…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.